JPMorgan analyst Eric Joseph downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Neutral.The analyst comments "We are downgrading PLRX shares ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE